Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was a single-center, randomized controlled pilot study. To explore the cardioprotective effect of cardiopeptidin on non-heart disease patients with severe cardiac injury by comparing whether cardiopeptidin was used.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cardiopeptidin | Experimental | Cardiopeptidin was administered intravenously once a day with 60mg of cardiopeptide for 3 days |
|
| 50 ml of normal saline intravenous infusion | Placebo Comparator | 50 ml of normal saline intravenous infusion. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cardiopeptidin | Drug | Cardiopeptidin was administered intravenously once a day with cardiopeptidin for 3 days.The dosing regimen follows the recommended dosage of 1 mg/kg/day as outlined in the product manual, with doses calculated based on the ideal body weight. |
| Measure | Description | Time Frame |
|---|---|---|
| major adverse cardiac events | major adverse cardiac events | On the day of enrollment, until 28 days. |
| Measure | Description | Time Frame |
|---|---|---|
| 28-day all-cause mortality | 28-day all-cause mortality | 28-day |
| 90-day all-cause mortality | 90-day all-cause mortality | 90-day |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| zhenhua zeng | Nanfang Hospital, Southern Medical University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Southern medical university Nanfang hospital | Guangzhou | 510515 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 50 ml of normal saline intravenous infusion | Drug | 50 ml of normal saline intravenous infusion |
|
| Cardiac adverse events | Cardiac adverse events | In hospital, until the patient is discharged. |
| LVEF | LVEF | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| APACHE II | APACHE II | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| Hypersensitive troponin T | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| MB | MB | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| NT-Pro BNP | NT-Pro BNP | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| LDH | LDH | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| α-HBDH | α-HBDH | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| CK | CK | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| CKMB | CKMB | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| Lac | Lac | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |